Medicine is undergoing a transformation, with innovation wherever you look. Oxford, Cambridge and London are the centre of a network that extends nationwide.
To develop the best strategy for your biotech business, you need inside knowledge. We have insight into the science, with experience across a range of biomedical research from drug design and manufacture to preclinical testing, imaging and clinical trials of novel agents and devices.
We also have insight into your potential markets. Is your product destined for the NHS? Do you know the priorities of NHS purchasers? Have you talk to the patients who could benefit from your technology? What are their perspectives?
Have you done your scientific due diligence?
Biotech investors want to do good. But they often focus on what they understand best – financing, corporate structure, accountability – and are tempted to leave the science to the CSO.
If you are going to invest in a biotech venture, you need to question the science too. Is the clinical question clear? Is the intervention defined? Do the outcome measures make sense, and are they actually measurable? What statistical power governs study size? What is the series of preclinical and clinical studies that would make a compelling scientific story that takes the product to market?
We can work with you to ask the right questions to guide your investment and development.